AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11367647
Drug: Xuefuzhuyu Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefuzhuyu Pill (XFZYP) 6 g, three times daily for one month
Trial: 11367647
Drug: Aspirin 40
RxNorm normalized name: aspirin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 40 mg per day for one month
Trial: 3142509
Drug: Alfentanil priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil priming infusion (60 micrograms kg‐1 min‐1 for 10 min) followed by maintenance infusion (4.5 micrograms kg‐1 min‐1) with lorazepam 0.08 mg kg‐1 by mouth 1-2 h before operation.
Trial: 3142509
Drug: Alfentanil maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil maintenance infusion rates of 5.4 (n = 4), 6.6 (n = 5), or 7.8 (n = 4) micrograms kg‐1 min‐1, each preceded by a proportional priming infusion with lorazepam 0.04 mg kg‐1 by mouth as premedication.
Trial: 21176724
Drug: Erdosteine (E)
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (E) 300 mg b.i.d. for 10 days
Trial: 18339162
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg/kg and ketamine 0.5 mg/kg
Trial: 10926377
Drug: 4 puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 puffs (0.4 mg) via MDI with spacer
Trial: 10926377
Drug: 10 puffs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 puffs (1.0 mg) via MDI with spacer
Trial: 10926377
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg via SVN
Trial: 14621850
Drug: OKT3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 (5 mg)
Trial: 26673577
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m2 plus carboplatin area under the curve 2 mg×min/mL
Trial: 26673577
Drug: gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m2 plus carboplatin area under the curve 2 mg×min/mL
Trial: 20958995
Drug: Hands-on passive
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hands-on passive stretching treatment procedures directed to the talocrural joint, varying in treatment speed, during the post-acute injury period.
Trial: 16968578
Drug: ALN +
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN + D (alendronate 70 mg and cholecalciferol 70 microg)
Trial: 16968578
Drug: ALN (alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN (alendronate 70 mg)
Trial: 9241384
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 4 days, total 1200 mg)
Trial: 9241384
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 6 days, total 1600 mg)
Trial: 27502729
Drug: FEC →
RxNorm normalized name: Fluorouracil, Epirubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC → D (epirubicin 75 mg/m², 5-fluorouracil 500 mg/m², cyclophosphamide 500 mg/m² every 2 weeks for 4 cycles, followed by docetaxel 75 mg/m² every 2 weeks for 4 cycles)
Trial: 27502729
Drug: TC (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (docetaxel 75 mg/m² and cyclophosphamide 600 mg/m² every 21 days for 6 cycles)
Trial: 20814844
Drug: Prefeeding oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefeeding oral stimulation program (5-min duration)
Trial: 20814844
Drug: Prefeeding oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefeeding oral stimulation program
Trial: 19211712
Drug: 128 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 128 mg/d candesartan
Trial: 19211712
Drug: 16 mg/d
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/d candesartan
Trial: 10475315
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 800 microg
Trial: 10475315
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 200 microg
Trial: 10475315
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 2 mg
Trial: 10475315
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 800 microg and Intravenous morphine 10 mg
Trial: 6213382
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (ipratropium bromide + fenoterol + theophylline)
Trial: 6213382
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination
Trial: 19864673
Drug: Trimethoprim-sulfamethoxazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (2 mg of trimethoprim plus 10 mg of sulfamethoxazole per kilogram of body weight) for 12 months
Trial: 17080491
Drug: Flexible method
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible method for extensions of fixed sample or group-sequential trials with t-distributed test statistics
Trial: 12743236
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 400 mg/d
Trial: 12743236
Drug: Valproate (VPA)
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate (VPA) 2,250 mg/d
Trial: 1487624
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg)
Trial: 24424707
Drug: Vortioxetine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 2.5 mg
Trial: 18621986
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg (Group K)
Trial: 18621986
Drug: Ketamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.25 mg + Midazolam 37.5 microg kg(‐1) (Group KM)
Trial: 16098435
Drug: Tadalafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (100 mg by mouth)
Trial: 16098435
Drug: Ibutilide (0.002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (0.002 mg/kg intravenously)
Trial: 28056945
Drug: Locally produced
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally produced lipid-based nutrient supplement (Wawamum) for children 6-23 months, micronutrient powders for children 24-59 months, and wheat soya blends for pregnant and lactating mothers.
Trial: 24121757
Drug: TMC310911 (75‐2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 (75‐2000 mg)
Trial: 24121757
Drug: TMC310911 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 (300 mg bid, 600 mg once daily, 150 mg bid plus 100 mg ritonavir bid, 900 mg bid alone, 300 mg bid plus ritonavir 50 mg bid)
Trial: 24121757
Drug: TMC310911 (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 (1200 mg single-dose)
Trial: 24121757
Drug: TMC310911 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 (up to 2000 mg) and multiple-dose (up to 900 mg)
Trial: 7859961
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen (2 L/minute) via nasal cannula
Trial: 31942744
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block (0.5 mL/kg bupivacaine 0.25% every eight hours)
Trial: 31942744
Drug: Paracetamol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (15 mg/kg intravenously every eight hours)
Trial: 30884335
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for 10 days
Trial: 28299294
Drug: Chamomile cream
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile cream (0.5 g applied twice a day for 10 days)
Trial: 28299294
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (applied twice a day for 10 days)
Trial: 21327805
Drug: Dexmedetomidine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2.5 μg/kg
Trial: 16896874
Drug: Microcurrent skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent skin patch (MCT) plus tramadol hydrochloride
Trial: 16388069
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day ethyl-EPA
Trial: 16388069
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day ethyl-EPA
Trial: 1768820
Drug: Sodium thiopental
RxNorm normalized name: Thiopental Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental (3 mg/kg)
Trial: 6803909
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses (regimen I)
Trial: 6803909
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high doses (regimen II)
Trial: 21086591
Drug: Magnetolaser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetolaser therapy in combination with whole body iodine‐bromide‐sodium chlorine baths, physical exercises, and massage
Trial: 19014552
Drug: Education program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education program (structured dialogue conveying information about pathophysiology, pharmacological and non‐pharmacological treatment of GERD, patients' rights and use of healthcare)
Trial: 11842293
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy for 3 years
Trial: 1723461
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg once daily for 4 months)
Trial: 1723461
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg once daily for 4 months)
Trial: 25801231
Drug: Pseudomonas aeruginosa
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas aeruginosa preparation (PAP)
Trial: 18042619
Drug: Preventive pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive pacing with four therapies
Trial: 15058255
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CABG and TMLR (CABG/TMLR group)
Trial: 10736287
Drug: Intravenous T(3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous T(3) at 0.4 microg/kg
Trial: 10736287
Drug: Intravenous T(3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous T(3) at 0.6 microg/kg
Trial: 10736287
Drug: Intravenous T(3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous T(3) at 0.8 microg/kg
Trial: 8725414
Drug: Hypothermic CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic CPB (rectal temperature 27 to 28 degrees C)
Trial: 8725414
Drug: Normothermic CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic CPB (rectal temperature > 36 degrees C)
Trial: 28923492
Drug: ECA/Kardia intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECA/Kardia intervention (smartphone-based Embodied Conversational Agent and Alive Cor Kardia Mobile heart rhythm monitor)
Trial: 20711135
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of alpha lipoic acid for two months
Trial: 20711135
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of gabapentin for two months
Trial: 20711135
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 600 mg/day of alpha lipoic acid and 300 mg/day of gabapentin for two months
Trial: 20711135
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of cellulose starch for two months
Trial: 19907100
Drug: Pitavastatin 2
RxNorm normalized name: PITAVASTATIN 2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg/day for 12 months
Trial: 11557159
Drug: Ketamine (0.1‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.1‐0.5 mg/kg)
Trial: 9500318
Drug: sublingual/oral immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual/oral immunotherapy
Trial: 8719303
Drug: Repeated hexarelin
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated hexarelin administration
Trial: 2703387
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) 1 g/m2/d with brachytherapy for ENT tumors
Trial: 2703387
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) 1 g/m2/d with hypofractionated external radiotherapy for breast cancer
Trial: 2703387
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) 1 g/m2/d with hypofractionated external radiotherapy for large ENT tumors
Trial: 329375
Drug: Secretolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secretolytic agents
Trial: 31971034
Drug: Antipsoriatic drugs
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antipsoriatic drugs (10 drugs including 3 oral medications and 7 biologic agents)
Trial: 31971034
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of treatment alone
Trial: 22070722
Drug: Physiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy with respiratory therapy and 'hot roll' treatment on radiation treatment days.
Trial: 16278069
Drug: Aceclofenac administered
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac administered preoperatively (2 tablets of 100 mg taken orally 1h before surgery)
Trial: 16278069
Drug: Aceclofenac administered
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aceclofenac administered postoperatively (2 tablets of 100 mg taken orally in the early postoperative period)
Trial: 8961972
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy beyond 5 years
Trial: 8961972
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy for estrogen receptor-positive tumors
Trial: 1842806
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral quinine (1050 mg in two divided doses daily for five days)
Trial: 7129168
Drug: Problem-solving training
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving training (practical solutions for everyday difficulties)
Trial: 3907823
Drug: Bromocriptine, 18-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine, 18-150 mg/day (mean, 72.5)
Trial: 27283947
Drug: Vinpocetine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 30 mg intravenously once daily for 7 days
Trial: 27283947
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cytidine disphosphate choline + aspirin/clopidogrel)
Trial: 22652556
Drug: Calcifediol (Hidroferol®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol (Hidroferol®, 1 ampoule: 266 μg) administered weekly after HD for 6 doses
Trial: 18818572
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + cilostazol
Trial: 15879923
Drug: 0.05 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/day vaginal ring
Trial: 15879923
Drug: 0.1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/day vaginal ring
Trial: 15879923
Drug: 0.0075 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0075 mg/day vaginal ring (active comparator)
Trial: 8759656
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg qAM
Trial: 8759656
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg qPM
Trial: 8759656
Drug: All regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All regimens of omeprazole 40 mg
Trial: 6759285
Drug: Verapamil 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 480 mg daily
Trial: 6759285
Drug: Nifedipine 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 60 mg daily
Trial: 31285414
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Tranexamic Acid (TXA) 1.5 g in 50 ml normal saline
Trial: 11994058
Drug: Chlorpheniramine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine alone (8 mg)
Trial: 11994058
Drug: Chlorpheniramine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine with quinidine (50 mg every 6 h for 2 days prior and during the study)
Trial: 10654755
Drug: Aminophylline cream
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline cream applied twice daily to one thigh/buttock (placebo on the other)
Trial: 10654755
Drug: Endermologie treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endermologie treatment applied twice weekly to one thigh/buttock
Trial: 10654755
Drug: Endermologie treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endermologie treatment applied to both thighs/buttocks with the same cream regimen as group 1
Trial: 9121998
Drug: Before treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before treatment (I)
Trial: 9121998
Drug: On the
RxNorm normalized name: Meds on the Go KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the 3rd treatment week (II)
Trial: 1929772
Drug: Clomipramine hydrochloride
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine hydrochloride (mean dose 120 +/- 48 mg/d)
Trial: 1929772
Drug: Desipramine hydrochloride
RxNorm normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine hydrochloride (mean dose 135 +/- 53 mg/d)
Trial: 22676430
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) provided by MSWs in clients' homes
Trial: 12149503
Drug: Cetirizine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (0.25 mg/kg twice a day over 18 months)
Trial: 7650070
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 50 mg flurbiprofen
Trial: 7650070
Drug: Single topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single topical application of a 40 mg flurbiprofen patch
Trial: 7650070
Drug: Repeated application
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated application of the topical patch (twice daily for 7 days)
Trial: 7650070
Drug: Topical patch
RxNorm normalized name: Mega Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical patch
Trial: 2745390
Drug: Fenfluramine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine 1.5 mg/kg daily for 3 months
Trial: 31047901
Drug: Data-driven cluster
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data-driven cluster analysis for selecting glucose-lowering therapy
Trial: 23768260
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus exposure therapy
Trial: 19157318
Drug: Methadone (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (20-60 mg daily, tapered over 2 weeks)